Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-debate-20260410-113045-27c7b314_20260421-011124",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "propose",
  "content": "TRPML1 should be treated as a pulsatile lysosomal signalling target rather than as a simple gain-of-function switch. The key mechanistic hypothesis is that moderate TRPML1 activation creates local lysosomal Ca2+ microdomains that activate calcineurin, promote TFEB nuclear entry, and increase autophagosome-lysosome fusion, but sustained high activation drains the same Ca2+ pool needed for hydrolase function, membrane repair, and lysosome re-acidification. This explains why the same axis can look therapeutic in Alzheimer-related endosomal-autophagic-lysosomal models yet toxic when activation is excessive or poorly timed.\n\nHypothesis 1: sequential autophagy priming followed by TRPML1 activation creates a wider therapeutic window than simultaneous high-dose activation. Rapamycin or another autophagy primer would first increase autophagosome flux and lysosomal biogenesis demand; a delayed low-dose TRPML1 agonist would then supply the Ca2+-dependent TFEB/fusion signal when the lysosomal network can use it. The falsifiable prediction is that delayed ML-SA1-like agonism improves LC3-II turnover, p62 clearance, cathepsin activity, and TFEB nuclear localization more than either drug alone, while preserving lysosomal Ca2+ measured with lysosome-targeted sensors.\n\nHypothesis 2: TRPML1 benefit depends on mitochondrial quality-control context. In PINK1/Parkin-competent neurons, TRPML1 activation can couple mitophagosome delivery to TFEB-driven lysosome replenishment; in PINK1/Parkin-deficient or LRRK2-hyperactive contexts, the same stimulus may generate lysosomal stress because damaged mitochondria continue feeding ROS and iron stress into an already overloaded lysosomal compartment. The falsifiable prediction is genotype stratification: MCOLN1 agonism should rescue alpha-synuclein or tau aggregate clearance in PINK1/Parkin-intact neurons but show a narrower or inverted dose response in PINK1/PARK2 loss-of-function models.\n\nHypothesis 3: the clinically relevant biomarker is not bulk TRPML1 activation but the ratio of lysosomal Ca2+ release to lysosomal reserve. A therapeutic dose should transiently increase TFEB target expression and autophagic flux without increasing galectin puncta, lysosomal membrane permeabilization, cytosolic cathepsins, or lipid peroxidation. A toxic dose should show early Ca2+ depletion, impaired hydrolase maturation, and membrane damage before cell death. The Alzheimer ML-SA1 rescue literature and lysosomal calcium reviews support the benefit side, while TRPML1 biology as the lysosomal Ca2+ retaker explains why depletion toxicity is plausible.\n",
  "tokens_used": "650"
}